Cargando…
Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371
European Pharmacopoeia monograph 2371 describes the production of homeopathic preparations. A specific efficacy of these preparations in high dilution levels is questionable in view of basic scientific principles. There is empirical evidence for such effects, for example in a Lemna-intoxication bioa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944999/ https://www.ncbi.nlm.nih.gov/pubmed/35327354 http://dx.doi.org/10.3390/biomedicines10030552 |
_version_ | 1784673846568157184 |
---|---|
author | Ücker, Annekathrin Baumgartner, Stephan Martin, David Jäger, Tim |
author_facet | Ücker, Annekathrin Baumgartner, Stephan Martin, David Jäger, Tim |
author_sort | Ücker, Annekathrin |
collection | PubMed |
description | European Pharmacopoeia monograph 2371 describes the production of homeopathic preparations. A specific efficacy of these preparations in high dilution levels is questionable in view of basic scientific principles. There is empirical evidence for such effects, for example in a Lemna-intoxication bioassay published 2010. To test the replicability and robustness of this bioassay, we conducted two experimental series (five independent blinded and randomised experiments each). The specimen of Lemna gibba L., clone-number 9352, were stressed in arsenic solution for 48 h (158 mg/L AsNa(2)HO(4) (250 mg/L in series 2)), then grew in either As(2)O(3) preparations produced according to Eu. Pharm. Monogr. 2371 or control solution. Comparing the area-related relative growth rate of day 3–9 (rgr 3–9) between treatment and control groups for each series showed differences that were not significant in series 1 (p = 0.10), significant in series 2 (p = 0.04) and significant in the pooled data of both series (p < 0.01). The effect direction (rgr 3–9 increase) was comparable to experiments of 2010, but the effect size was smaller, likely due to a changed light cycle. These results are not compatible with the hypothesis that the application of European Pharmacopoeia monograph 2371 results in pharmaceutical preparations without specific effects. Further studies are needed to investigate a potential mode of action explaining these effects. |
format | Online Article Text |
id | pubmed-8944999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89449992022-03-25 Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371 Ücker, Annekathrin Baumgartner, Stephan Martin, David Jäger, Tim Biomedicines Article European Pharmacopoeia monograph 2371 describes the production of homeopathic preparations. A specific efficacy of these preparations in high dilution levels is questionable in view of basic scientific principles. There is empirical evidence for such effects, for example in a Lemna-intoxication bioassay published 2010. To test the replicability and robustness of this bioassay, we conducted two experimental series (five independent blinded and randomised experiments each). The specimen of Lemna gibba L., clone-number 9352, were stressed in arsenic solution for 48 h (158 mg/L AsNa(2)HO(4) (250 mg/L in series 2)), then grew in either As(2)O(3) preparations produced according to Eu. Pharm. Monogr. 2371 or control solution. Comparing the area-related relative growth rate of day 3–9 (rgr 3–9) between treatment and control groups for each series showed differences that were not significant in series 1 (p = 0.10), significant in series 2 (p = 0.04) and significant in the pooled data of both series (p < 0.01). The effect direction (rgr 3–9 increase) was comparable to experiments of 2010, but the effect size was smaller, likely due to a changed light cycle. These results are not compatible with the hypothesis that the application of European Pharmacopoeia monograph 2371 results in pharmaceutical preparations without specific effects. Further studies are needed to investigate a potential mode of action explaining these effects. MDPI 2022-02-25 /pmc/articles/PMC8944999/ /pubmed/35327354 http://dx.doi.org/10.3390/biomedicines10030552 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ücker, Annekathrin Baumgartner, Stephan Martin, David Jäger, Tim Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371 |
title | Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371 |
title_full | Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371 |
title_fullStr | Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371 |
title_full_unstemmed | Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371 |
title_short | Critical Evaluation of Specific Efficacy of Preparations Produced According to European Pharmacopeia Monograph 2371 |
title_sort | critical evaluation of specific efficacy of preparations produced according to european pharmacopeia monograph 2371 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944999/ https://www.ncbi.nlm.nih.gov/pubmed/35327354 http://dx.doi.org/10.3390/biomedicines10030552 |
work_keys_str_mv | AT uckerannekathrin criticalevaluationofspecificefficacyofpreparationsproducedaccordingtoeuropeanpharmacopeiamonograph2371 AT baumgartnerstephan criticalevaluationofspecificefficacyofpreparationsproducedaccordingtoeuropeanpharmacopeiamonograph2371 AT martindavid criticalevaluationofspecificefficacyofpreparationsproducedaccordingtoeuropeanpharmacopeiamonograph2371 AT jagertim criticalevaluationofspecificefficacyofpreparationsproducedaccordingtoeuropeanpharmacopeiamonograph2371 |